Bal Pharma share news, announcements and annual reports
NSE: BALPHARMABSE: 524824Pharmaceuticals & BiotechnologySmall Cap
Bal Pharma Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, May 2006 on NSE
Last close ₹81.85down ₹2.76 (3.26%)BSE ₹81.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹84.61.
30 Oct: open ₹84.05, high ₹84.05, low ₹81.21
52-week range of traded prices to 30 Oct 2026
₹60.00Low, 30 Mar 2026₹124.60High, 10 Sep 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹130 Cr2,779th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 18.08
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.47%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.94
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 6,401
Bal Pharma share news and announcements
549 announcements, routine notices left out, newest first. Page 9 of 11.
Jan 2016
Dec 2015
Nov 2015
Oct 2015
Sep 2015
Aug 2015
14 Aug · Meeting
Register of Members and Share Transfer Books of the Company will remain closed from September 18, 2015 to September 22, 2015 (both days inclusive) to ascertain the entitlement of dividend and Annual General Meeting of the Company scheduled to be held on September 22, 2015.
Jul 2015
May 2015
30 May · Dividend
Board of Directors of the Company at its meeting held on May 29, 2015 has recommended a dividend of Re. 1/- per Equity Share of Rs. 10 each i.e 10% on the paid up equity share capital of the Company, for the financial year ended March 31, 2015.
Apr 2015
Mar 2015
Feb 2015
Nov 2014
Oct 2014
31 Oct · Board meeting
Inter alia will be taking on record and approve the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2014.20 Oct · Business
Board of Directors in its meeting held on October 20, 2014 has approved the issue and allotment of 13,00,000 warrants to the subscribers on preferential basis, at a conversion price of Rs.62/- per warrant.16 Oct · Board meeting
Board of Directors inter alia will consider issue and allotment of warrants to the investors on preferential basis.
Aug 2014
Jul 2014
30 Jul · Board meeting
Inter alia will be taking on record and approve the Un-Audited financial results of the Company for the quarter ended June 30, 2014.
Jun 2014
May 2014
29 May · Results
29 May · Dividend
Board of Directors of the Company at its meeting held on May 28, 2014 has recommended payment of dividend of Re. 1/- (10%) per Equity Share of Rs. 10 each.9 May · Board meeting
Inter alia will be transacting the following business, 1. Consideration of the Audited Financial Results of the Company for the IVth quarter and financial year ended 31.03.2014. 2. Appropriation of profits including recommendation of Dividend, if any. 3. Consideration of various subjects relating to Annual General Meeting. 4. Book closure and Convening of A.G.M . 5. Any other business with the permission of the Chairman.
Apr 2014